Lia DeGroot

Jeanne Mar­raz­zo, di­rec­tor of the di­vi­sion of in­fec­tious dis­eases at the Uni­ver­si­ty of Al­aba­ma at Birm­ing­ham, will take over An­tho­ny Fau­ci’s long­time role as head

Af­ter the FDA pub­lished draft guid­ance in June on de­vel­op­ing drugs to help pre­vent mi­graines, two com­pa­nies in this space are ask­ing the agency to

The FDA un­veiled its user fee rates for pre­scrip­tion drugs, biosim­i­lars, gener­ics and med­ical de­vices last Fri­day — and with the ex­cep­tion of biosim­i­lar ap­pli­cants,

Re­pub­li­can law­mak­ers re­leased a draft of a new bill that aims to stem drug short­ages af­ter Re­pub­li­cans in the House En­er­gy and Com­merce Com­mit­tee blocked ef­forts

A bi­par­ti­san group of sen­a­tors in­tro­duced leg­is­la­tion on Thurs­day that aims to bol­ster do­mes­tic gener­ic man­u­fac­tur­ing in an ef­fort to shore up stock­piles of key

Law­mak­ers have spent the spring and sum­mer chip­ping away at re­forms to phar­ma­cy ben­e­fit man­agers — the mid­dle­men en­ti­ties that in­sur­ance com­pa­nies hire to ne­go­ti­ate

Boehringer In­gel­heim and Eli Lil­ly said Jar­diance re­ceived ap­proval in Eu­rope as a treat­ment for chron­ic kid­ney dis­ease in adults, with the FDA’s de­ci­sion on

Ver­ri­ca Phar­ma­ceu­ti­cals’ drug-de­vice com­bi­na­tion prod­uct is now the first FDA-ap­proved treat­ment for mol­lus­cum con­ta­gio­sum, a com­mon skin in­fec­tion. On Fri­day the FDA ap­proved Ycanth, a

The FTC on Thurs­day cau­tioned phar­ma­cy ben­e­fit man­agers against re­ly­ing on the agency’s pre­vi­ous state­ments and stud­ies in sup­port of PBMs, the mid­dle­men who ne­go­ti­ate

The House En­er­gy & Com­merce Com­mit­tee ad­vanced its pan­dem­ic pre­pared­ness reau­tho­riza­tion leg­is­la­tion Wednes­day, de­spite firm op­po­si­tion from the pan­el’s De­moc­rats who al­so rein­tro­duced their own